Separating fact from fiction: Will the new weight loss drugs protect your heart?

With Lily N. Dastmalchi, DO
Tuesday, February 11, 2025
7 to 8 p.m.

A free heart Ask the Expert lecture presented by Inova

The U.S. Food and Drug Administration recently approved new weight loss medications to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease who are obese or overweight and do not have diabetes.

Join Inova cardiologist Lily Dastmalchi, DO, for an interactive discussion about the pros and cons of weight loss drugs like Ozempic^® and Wegovy^® and learn if you are a good candidate for these medications. Dr. Dastmalchi’s clinical interests include preventive cardiology, nutrition and women's cardiometabolic syndromes.

See all upcoming free webinars for Heart Month 2025 

Why it matters:

Heart disease is the leading cause of death for men and women in the United States. As projections show that more than half of the world’s population will be overweight or obese by 2035, these medications could improve health and quality of life and reduce healthcare costs for people living with obesity and subsequent medical complications like heart failure.

Your next step:

Register to learn more about the role of the new weight loss drugs in managing heart disease.

Important:

Participants must also register with Zoom to join the live event. The link will be included in your confirmation email from Inova.